Position paper 8 Feb 2024

Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future

This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.

Read more
Statement 6 Feb 2024

IFPMA statement ahead of the opening of the fourth WHO Fair Pricing Forum

The fourth meeting of the WHO’s Fair Pricing Forum represents an important opportunity to discuss how the global health community can work together to improve access to medicines and vaccines, deliver on the ambition of the Sustainable Development Goals (SDGs), and to achieve Universal Health Coverage (UHC) by 2030. IFPMA and our members continue to be committed to these goals and welcome the opportunity to share perspectives on how we can work together to achieve them.

Read more
Statement 5 Feb 2024

7th Meeting of the Working Group on Amendments to the International Health Regulations (2005)

On 5 February, IFPMA delivered a statement at the 7th Meeting of the Working Group on Amendments to the International Health Regulations (2005) in Geneva, Switzerland.

Read more
Expert insight 2 Feb 2024

Access to medicines and vaccines is about much more than price

Medical breakthroughs provide hope to patients, families and caregivers all over the world. However, we know that these ground-breaking advances in healthcare are only meaningful when they can reach the people who need them. To be successful, we need to be as innovative in our approaches to patient access as we are in the scientific discovery and development of medicines and vaccines themselves.

Read more
Expert insight 30 Jan 2024

Applying lessons learned on regulatory agility: Perspectives from national regulatory authorities

Regulatory agility played a crucial role in speeding up the development and approval of medicines and vaccines during the COVID-19 pandemic. The insights gained from this success are valuable for continually strengthening regulatory frameworks, both in emergency and non-emergency situations. IFPMA collaborated with external researchers to gather insights from national regulatory authorities and pharmaceutical companies on the success factors behind regulatory agility, especially ahead of future pandemics.

Read more
Report 30 Jan 2024

Lessons from regulatory agilities during the COVID-19 pandemic: views from members of National Regulatory Authorities

This report aims to explore the perspective of members of NRAs on the use of regulatory agilities which emerged during the COVID-19 pandemic and describe lessons learnt from this experience.

Read more
Statement 26 Jan 2024

EB154 individual statement on antimicrobial resistance (AMR)

On 24 January, IFPMA delivered a statement on antimicrobial resistance (AMR) at the WHO 154th Executive Board in Geneva, Switzerland.

Read more
Statement 25 Jan 2024

EB154 individual statement on health emergencies

On 25 January, IFPMA delivered a statement on health emergencies at the WHO 154th Executive Board in Geneva, Switzerland.

Read more
Statement 24 Jan 2024

EB154 constituency statement on non-communicable diseases

On 24 January, IFPMA, GSCF, and IGBA delivered a joint constituency statement on non-communicable diseases and Universal Health Coverage (UHC) at the WHO 154th Executive Board in Geneva, Switzerland.

Read more
Expert insight 14 Dec 2023

Ways to strengthen the clinical research ecosystem in resource-limited settings

Encouraging clinical research in low-income settings is essential to tap into opportunities that can make a difference in patients’ lives. Sarah Adam, Associate Director, Regulatory Affairs at IFPMA, shares perspectives on key pillars to support this.

Read more
African researcher is seated at his desk. He holds a pen and is writing things down.
Expert insight 12 Dec 2023

Healthcare for all must be a goal shared by the global community

In September, some 200 Heads of State and top political decision-makers met in New York for the annual United Nations General Assembly. They recommitted to the UN Sustainable Development Goals (SDGs), with a political declaration pledging to “act with urgency to realize the [Agenda 2030] vision.” Halfway to 2030 and with the clock ticking, the renewal...

Read more
Statement 7 Dec 2023

6th Meeting of the Working Group on Amendments to the International Health Regulations (2005)

On 7 December, IFPMA submitted a statement to the 6th Meeting of the Working Group on Amendments to the International Health Regulations (2005), happening in Geneva, Switzerland.

Read more